Featured
Boston, MA Nov. 18 – Medisafe, the premier platform for medication management and patient retention, is announcing several groundbreaking partnerships with major pharmaceutical brands in 2024, including two program launches with top US pharma brands in the past 30 days using Medisafe Maestro (see a demo). The releases underscore Medisafe’s unmatched ability to drive innovation…
Read More
By Omri Shor Medisafe Founder and CEO For too long, the pharmaceutical industry has been content with the status quo—relying on outdated, single-channel approaches to engage patients. But the world has changed, and patients demand more. At Medisafe we recognize that the future of patient engagement is no longer confined to a single app or…
Read More
BOSTON, MA / ACCESSWIRE / September 5, 2024 / Medisafe today unveiled a game-changing expansion of its omnichannel digital platform, setting a new standard for patient engagement and retention across the pharmaceutical landscape. Patients can now seamlessly interact with digital solutions through text, web, mobile apps, wearables, and tablets-no longer confined to a single app…
Read More
We’ll be talking PDURS, omni-channel scaling, behavioral data insights and our compliant comprehensive solutions for pharma brands that can launch in 90 days. See more about what we’ll be talking about and schedule time to chat here.
Read More
Want to keep current on the FDA’s Draft Guidelines for Prescription Drug Use Related Software (PDURS)? Follow the LinkedIn profiles of these professionals at the forefront of integrating digital health solutions with pharmaceutical products affected by PDURS. PDURS: The Agency Perspective Martin Culjat, PhD, Eversana – Martin Culjat is the Senior Vice President and Global…
Read More
The FDA’s Draft Guidelines for Prescription Drug Use Related Software (PDURS) have sparked considerable discussion among various stakeholders, including pharmaceutical companies, healthcare organizations, and digital health advocates. While praising and supporting the FDA’s work to issue clear guidance, most also had specific requests for additional clarity, especially about clinical trial requirements for digital health software…
Read More
The FDA’s new Draft Guidelines for Prescription Drug Use Related Software (PDURS) are shaping the future of digital health in the pharmaceutical industry. These guidelines aim to ensure the safety and efficacy of software that supports prescription drug use, marking a pivotal moment for digital health professionals. As executives at the forefront of pharmaceutical digital…
Read More
As the digital health landscape evolves, pharmaceutical companies must adapt to new regulatory frameworks that ensure patient safety and product efficacy. The FDA’s Draft Guidelines for Prescription Drug Use Related Software (PDURS) mark a significant step in this direction, providing comprehensive standards for software intended to support prescription drug use. For pharmaceutical brand marketers and…
Read More
In an era where digital health tools are becoming increasingly integrated into healthcare delivery, regulatory frameworks must adapt to ensure these innovations are safe, effective, and beneficial to patients. The FDA’s Prescription Drug Use Related Software (PDURS) guidance is a significant step in this direction. This guidance focuses on software intended to support the use…
Read More